27/09/2026
One highlight in ASTRO is Monday’s press briefing, featuring several exciting late-breaking studies, including:
- A Randomized, Phase II Clinical Trial of Stereotactic Body Radiation Therapy or Conventionally Fractionated Concurrent Chemotherapy and Radiation Therapy Preoperatively for Pancreatic Adenocarcinoma, the SOFT Preop Study (Abstract LBA 08), presented by William Hall, MD
- Alliance A071801 Phase III Trial Postoperative Single Fraction Stereotactic Radiosurgery (SRS) vs. Fractionated SRS (fSRS) for Resected Brain Metastasis (Abstract LBA 01), presented by Ayal Aizer, MD
- Efficacy of Radical Prostatectomy Versus Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer: Results from an international Phase III Randomized Controlled Trial (PACE–A) (Abstract LBA 32), presented by Nicholas van As, MD
- NRG-CC009: A Phase III Trial of Stereotactic Radiosurgery (SRS) vs. Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Brain Metastases from Small Cell Lung Cancer (SCLC) (Abstract LBA 02), presented by Chad Rusthoven, MD
- Phase II Multi-institutional Study of Ultralow-dose (4Gy) Response-adapted Radiotherapy for Symptomatic Bone Metastases from Multiple Myeloma (Abstract 10), presented by Leslie Ballas, MD, FASTRO
Moderated by Beth Erickson, MD, FASTRO, incoming ASTRO President-elect
Information for media professionals covering the ASTRO 2026 Annual Meeting